apoptotic protease Ced3 and the mammalian interleukin-l(~ converting enzyme (Femandes-Alnemri et al., 1994) . The purification of Apopain unified the biochemistry of mammalian apoptosis with the genetics that had been established in C. elegans. But the crucial question remained: "What activates Apopain?"
Wang remembers Alnemri's paper vividly because it caused quite a stir in the laboratory of Joe Goldstein and Mike Brown. As a postdoctoral fellow in their lab, Wang was searching for a sterol-regulated protease that cleaves a pair of membrane bound transcriptional factors, SREBP-1 and -2. He used in vitro translated, 3~S-labeled SREBP-2 as a substrate and incubated it with cell extracts from large-scale cultures of HeLa cells. After several months of fruitless searching, he became rather desperate and somewhat sloppy. One Friday, he left some cytosolic extracts in a 4°C refrigerator for the entire weekend instead of freezing them at -80°C. On the following Monday, to his surprise he found an SREBP-2 cleavage activity (Sca) that was not there the previous Friday. After a brainstorming session with Brown and Goldstein, they postulated that there must be a latent activity that was slowly activated in the refrigerator. By raising the incubation temperature to 37°C, Wang reproduced the activation in only two hours.
In a few months, Wang and a graduate student, Jihtung Pai, purified this SREBP cleavage activity using classical biochemical fractionation methods. The sequence of the purified enzyme revealed a novel protein.
As they were in the process of cloning this protein, the paper describing the cloning of CPP32 appeared in JBC and to their astonishment the protein sequence of the SREBP cleavage enzyme was the same as CPP32. Unknowingly, they had been following the same path as *Correspondence: xwang@biochem.swmed.edu Nicholson, since SREBP-2, like PARP, proved to be a substrate for CPP32/Apopain (Wang et al., 1995) .
CPP32/Apopain/Sca, now universally known as caspase-3, is only activated in cells during apoptosis and (to Brown and Goldstein's disappointment) it was not the sterol-regulated protease that cleaves SREBP and regulates sterol homeostasis. Nonetheless, Wang remained intrigued about how caspase-3 becomes activated, At this point, Wang left the Brown/Goldstein laboratory and moved to Emory University where he started his own laboratory as an Assistant Professor. Wang decided to continue his studies of CPP32, focusing now on its activation in apoptosis. He first attempted to accelerate the activation reaction in vitro by adding small molecules including nucleotides and kinase or phosphatase inhibitors. Together with his first graduate student, Xuesong Liu, he found that ATP accelerates caspase-3 activation. When they compared the effect of ATP versus other nucleotides, they found, surprisingly, that dATP is 10-fold more active than ATP. By adding dATP to cytosolic extracts from nonapoptotic HeLa cells, they reduced the complicated process of apoptosis activation to a simple in vitro assay for caspase-3 activation. Using this assay and classical fractionation methods, they isolated in order the following three proteins that are necessary and sufficient for this reaction: cytochrome c, Apaf-1, and procaspase-9.
The Discovery
The paper by Li et al., 1997 that was chosen for this commemorative issue, was the third paper from Wang's laboratory that described our biochemical approach to apoptosis. This paper also combined our biochemical studies with the molecular biological work from Emad AInemri's group. The first paper identified cytochrome c as a necessary component for caspase-3 activation in vitro and made the observation that cytochrome c is released from mitochondria to cytosol during apoptosis (Liu et al., 1996) . For obvious reasons, this paper drew heavy criticism and frank disbelief for quite some time. The vital function of cytochrome c in the electron transfer chain was well accepted and difficult to reconcile with a proapoptotic activity. After all, in our first paper, we were unable to provide any mechanistic data explaining how cytochrome c activates caspase-3. At this point we left Emory and returned to Dallas where Wang became the first recruit to a new department of Biochemistry that was being created by Steve McKnight.
In Dallas we continued our work on apoptosis activation. The work led to our second paper, in which we purified a second factor necessary for caspase-3 activation and named it Apaf-1, which was subsequently cloned by Dr. Hua Zou. Remarkably, the sequence of Apaf-1 revealed partial homology to the C. elegans proapoptotic protein Ced4 (Zou et al., 1997) . For several years, the mammalian Ced4 homolog had defied identification. It remained the last missing piece of an apoptotic pathway that was otherwise conserved from humans to worms. Understandably, Apaf-1 received a much warmer welcome, than cytochrome c. Apaf-1 is about twice the size of Ced4. The N-terminal region of Apaf-1 resembles Ced4 and it was proposed to function as the caspase recruitment domain (CARD). The C-terminal extension of Apaf-1 contains multiple WD-40 repeats that are missing in Ced4. The finding that Apaf-1 binds cytochrome c helped clarifying the role of cytochrome c as an initiator of apoptosis.
By now our work was beginning to receive some positive attention. Our third paper, which described the mechanism by which cytochrome c and Apaf-1 activate caspase-3, established that a third protein was required for in vitro caspase-3 activation (Li et al., 1997) . This protein turned out to be procaspase-9, a "CARD-carrying" caspase. In this paper, we showed that caspase-9 initiates the caspase cascade by cleaving procaspase-3. Procaspase-9 is converted to the active caspase-9 after the CARD domains of procaspase-9 and Apaf-1 interact. The CARD-CARD interaction between Apaf-1 and procaspase-9 does not happen in the absence of cytochrome c and ATP/dATP. In the presence of ATP/dATP, cytochrome c binding to Apaf-1 induces a conformation change of Apaf-1 that exposes its CARD so that it can recruit procaspase-9. An active-site mutant form of procaspase-9 suppressed the cytochrome c-initiated caspase-3 activation in a dominant-negative fashion, presumably by keeping the wild-type procaspase-9 from binding Apaf-1 CARD. To us, the most remarkable aspect of this whole story was the occurrence of the entire cytochrome C/Apaf-1/procaspase-9/procaspase-3 activation sequence in the refrigerator over the weekend in the Brown-Goldstein laboratory. Had these reactions not occurred, Wang would never have been introduced to apoptosis. From such improbable events, scientific careers do arise.
The Follow-Up
Caspase-9 proved to be unique in many ways. Rodriguez and Lazebnik found that unlike other caspases, free caspase-9 has minimal activity compared to Apaf-1 bound caspase-9 (Rodriguez and Lazebnik, 1999) . In another surprising finding made by Guy Salvesen and colleagues, procaspase-9 can be activated after binding to Apaf-1 even without proteolytic cleavage (Stennicke et al., 1999) . All other known caspases are activated only after proteolytic cleavage.
How is procaspase-9 activated when complexed with Apaf-1 ? We subsequently showed that Apaf-1 normally exists as a monomer, but in the presence of cytochrome c and ATP/dATP, Apaf-1 forms a much larger complex, termed "apoptosome" (Zou et al., 1999) . After cytochrome c binds to Apaf-1, Apaf-1 undergoes a conformational change that exposes a previously hidden nucleotide binding region that becomes accessible to free nucleotide. When nucleotide binds to Apaf-1, it drives the Apaf-1/cytochrome c complex to oligomerize into the apoptosome (Jiang and Wang, 2001) . By using cryo-EM technology, Chris Akey's group recently showed that the apoptosome exhibits a symmetrical wheel-like structure composed of seven molecules each of Apaf-1 and cytochrome c. The exposed N-terminal CARD domains of Apaf-1 form a central hub region, and the C-terminal WD40 repeats are extended to form the cytochrome c binding spikes (Acehan et al., 2002) . The cryo-EM structures containing procaspase-9 suggested that the CARD domains in the central hub effectively create an enriched local concentration of procaspase-9. The CARD domain interaction between Apaf-1 and caspase-9 may induce the enzyme to adopt a fully extended, active conformation that permits the formation of active dimer enzyme and autocalytic cleavage (Acehan et al., 2002) .
In as much as activated caspase-9 can be fatal, cells go to extraordinary lengths to prevent unintended caspase-9 activation. Even after cytochrome c is released, the cell uses XlAP (and possibly other lAPs) as a second tier regulator to extinguish unintended caspase-9 activation. XlAP is an antiapoptotic protein that binds to and inhibits the newly generated active N terminus of caspase-9 after autocatalysis (Shiozaki et al., 2003) . This inhibition is relieved by the release of lAP-antagonizing proteins from mitochondria including Smac/Diablo and Omi/HtrA2 (reviewed by Vaux and Silke, 2003) . The dual requirement for cytochrome c and either Smac/Diablo or Omi/HtrA2 acts like a coincidence circuit. Caspase-9 is activated only when both limbs of this circuit function simultaneously.
Apoptosis and Cancer
In order to become malignant, cancer cells must find a way to evade the apoptotic cascade, which otherwise would result in their elimination. This evasion also renders tumors resistant to apoptosis-inducing cytotoxic agents, including ionizing radiation. For these reasons many laboratories are searching for small molecules that can restore the blocked apoptosis in cancer cells. In one such search, Rosenberg et al. at Abbott Laboratories carried out a high throughput screen for compounds that activate caspase-3 in HeLa cell extracts (Jiang et al., 2003) . This screen revealed that ~-(trichloromethyl)-4-pyridineethanol promotes apoptosome formation. While studying how this chemical activates caspase-3, Dr. Xuejun Jiang in our lab found two other proteins that regulate apoptosome formation: prothymosin-~ and PHAP proteins. After apoptosome formation, caspase-9 recruitment and activation is enhanced by PHAP proteins, which are thereby tumor suppressors. Prothymosin-~ has the opposite effect: it inhibits apoptosome action, and therefore it is an oncoprotein. The small molecule ~-(trichloromethyl)-4-pyridineethanol activates apoptosome formation by blocking the inhibitory effect of prothymosin-c~ (Jiang et al., 2003) . Compounds that replicate this activity are potential anticancer agents.
The Remaining Questions
The most unexpected feature of caspase-9 activation pathway was that it is triggered by cytochrome c, a mitochondrial protein that is released to the cytosol so that it can bind Apaf-1, a cytosolic protein. The mitochondrial connection had not been made in the genetic experiments in invertebrates. Although Apaf-1 and caspase-9 have clear homologs in invertebrates like worms and fruit flies, we still do not know how these proteins are activated during apoptosis in these organisms. Recent work from Hermann Steller's laboratory indicates that a form of cytochrome c, cytochrome c-d, is critical for activating caspases during the differentiation of fly sperm, a process that shares many features with apoptosis (Arama et al., 2003) . Future biochemical studies using materials from these organisms should dispel many mysteries about the evolutionary origin of the mitochondrial role in apoptosis.
The role of the mitochondrial apoptosis pathway in postnatal tissue homeostasis can be studied in mammals by tissue-specific knockout of the genes involved. Germ-line knockout of Apaf-1, caspase-9, and caspase-3 revealed only their roles in neural development since mice without these genes die pre and perinatally of neural dysfunction (Kuida et al., 1996 (Kuida et al., , 1998 Yoshida et al., 1998) , Although purified Apaf-1, procaspase-9, procaspase-3, and cytochrome c are sufficient to reconstitute the caspase-3 activation cascade in vitro, we already know that other regulatory proteins contribute in vivo. Prothymosin-~ and PHAP proteins are two such proteins that have been identified recently. These two proteins need additional mediators. Hopefully, the biochemical identification of new apoptosis regulators will lead to more tumor suppressors or oncogenic proteins that can be targets of drug developments.
Introduction
Cell death occurs as a normal aspect of animal development as well as in tissue homeostasis and aging (Glucksmann, 1950; Ellis et al., 1991a) . Naturally occurring or programmed cell death can act to regulate cell number, to facilitate morphogenesis, to remove harmful or otherwise abnormal cells, and to eliminate cells that have already performed their functions. In many cases, gene expression within dying cells is thought to be required for these cells to die, since the cell death process can be blocked by inhibitors of RNA and protein synthesis (Stanisic et al., 1978; Cohen and Duke, 1984; Martin et al., 1988) .
During the development of the nematode Caenorhabditis elegans, 131 cells undergo programmed cell death (Sulston and Horvitz, 1977; Sulston et al., 1983) . Fourteen genes have been identified that function in different steps of the genetic pathway of programmed cell death in C. elegans (Hedgecock et al., 1983; Ellis and Horvitz, 1986, 1991; Ellis et al., 1991 b; Hengartner et al., 1992; reviewed by Ellis et al., 1991a) . Two of these genes, ced-3 and ced-4, play essential roles in either the initiation or execution of the cell death program, since recessive mutations in these genes prevent almost all of the cell deaths that normally occur during C. elegans development. Genetic mosaic analysis indicates that ced-3 and ced-4 most likely function within cells that die or within their close relatives to cause cell death (Yuan and Horvitz, 1990) . The ced-4 gene encodes a novel protein that is expressed primarily during embryogenesis, the period during which most programmed cell deaths occur (Yuan and Horvitz, 1992) .
To understand how the ced-3 gene acts to cause cell death, we have cloned this gene. As deduced from the sequence of a ced-3 cDNA clone, the CED-3 protein is 503 amino acids in length and contains a serine-rich middle region of about 100 amino acids. We compared the sequences of the CED-3 protein of C. elegans with the inferred CED-3 protein sequences from the related nematode species C. briggsae and C. vulgaris. This comparison revealed that the carboxy-terminal portions of these proteins are most conserved. The non-serine-rich portions of the CED-3 protein are similar to human interleukin-1 (IL-1 I~)-converting enzyme (ICE), a cysteine protease that can cleave the inactive 31 kd precursor of IL-113 to generate the active cytokine (Cerretti et al., 1992; Thomberry et al., 1992) . In addition, the carboxy-terminal portions of both the CED-3 and ICE proteins are similar to the mouse Nedd-2 protein, which is encoded by a messenger RNA (mRNA) expressed during mouse embryonic brain development and is down-regulated in adult brain (Kumar et al., 1992) . We suggest that CED-3 acts as a cysteine protease in controlling the onset of programmed cell death in C. elegans and that members of the ced-3/ICE/nedd-2 gene family might function in programmed cell death in vertebrates.
Results

ced-3 Is Not Essential for Viability
All previously described ced-3 alleles were isolated in screens designed to detect viable mutants in which programmed cell death did not occur (Ellis and Horvltz, 1986) . Such screens might systematically have missed classes of ced-3 mutations that result in inviability. Since animals of the genotype ced-3/deficiency are viable (Ellis and Horvitz, 1986) , we designed a screen that would allow us to isolate recessive lethal alleles of ced-3, if such alleles could exist (see Experimental Procedures). We obtained four new ced-3 alleles (n 1163, n 1164, n 1165, and n 1286) in this way. All four of these mutants are viable as homozygotes. These alleles were isolated at a frequency of about 1 in 2500 mutagenized haploid genomes, approximately the frequency expected for the generation of loss-offunction mutations in an average C. elegans gene (Brenner, 1974; Meneely and Herman, 1979; Greenwald and Horvitz, 1980) .
